Both CPIC [121] and DPWG (106) have produced clinical guidelines for clopidogrel-CYP2C19: CPIC focuses on ACS patients undergoing PCI, and DPWG on PCI for any indication, as well as stroke and TIA. This evidence concerns the gene CYP2C19 and transient ischemic attack.